Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.
Brand Name : AC-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2023
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?